By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on Biotechnology have been published. According to news reporting originating from Chongqing, People's Republic of China, by NewsRx correspondents, research stated, "Hepatic fibrosis is a major consequence of liver aggression. Finding novel ways for counteracting this damaging process, and for evaluating fibrosis with a non-invasive imaging approach, represent important therapeutic and diagnostic challenges."
Our news editors obtained a quote from the research from Chongqing Medical University, "Hepatocyte growth factor (HGF) is an anti-fibrosis cell growth factor that induces apoptosis in activated hepatic stellate cells, reduces excessive collagen deposition, and stimulates hepatocyte regeneration. Thus, using HGF in gene therapy against liver fibrosis is an attractive approach. The aims of the present study were: (i) to explore the efficacy of treating liver fibrosis using HGF expression vector carried by a novel ultrasound microbubble delivery system; (ii) to explore the diagnostic interest of diffusion-weighted MRI (DWI-MRI) in evaluating liver fibrosis. We established a rat model of hepatic fibrosis. The rats were administered HGF linked to novel ultrasound micro-bubbles. Progression of hepatic fibrosis was evaluated by histopathology, hydroxyproline content, and DWI-MRI to determine the apparent diffusion coefficient (ADC). Our targeted gene therapy produced a significant anti-fibrosis effect, as shown by liver histology and significant reduction of hydroxyproline content. Moreover, using DWI-MRI, the b value (diffusion gradient factor) was equal to 300s/mm(2), and the ADC values significantly decreased as the severity of hepatic fibrosis increased. Using this methodology, F0-F2 could be distinguished from F3 and F4 (P
According to the news editors, the research concluded: "DWI-MRI appears a promising imaging technique for evaluating liver fibrosis."
For more information on this research see: Efficacy of HGF carried by ultrasound microbubble-cationic nano-liposomes complex for treating hepatic fibrosis in a bile duct ligation rat model, and its relationship with the diffusion-weighted MRI parameters. Clinics and Research in Hepatology and Gastroenterology, 2013;37(6):602-607. Clinics and Research in Hepatology and Gastroenterology can be contacted at: Elsevier Masson, Via Paleocapa 7, 20121 Milano, Italy. (Elsevier - www.elsevier.com; Clinics and Research in Hepatology and Gastroenterology - www.elsevier.com/wps/product/cws_home/724708)
The news editors report that additional information may be obtained by contacting S.H. Zhang, Chongqing Med Univ, Affiliated Hosp 2, Inst Ultrasound Imaging, Chongqing 40016, People's Republic of China. Additional authors for this research include K.M. Wen, W. Wu, W.Y. Li and J.N. Zhao (see also technology.html">Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Chongqing, Gene Therapy, Bioengineering, Liver Fibrosis, Liver Cirrhosis, Gastroenterology, Hepatic Fibrosis, Hepatocyte Growth Factor, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC